Predictive Factors Shape Guselkumab Response in Psoriasis

TOPLINE: A new study found that 57.6% of patients with psoriasis achieved super responder status with guselkumab, characterised by complete skin clearance at week 20. Bio-naive status and lower comorbidity rates were associated with superior response, with 85% of super responders maintained Psoriasis Area and Severity Index (PASI) 100 at year 4…